文献速递神经核医学放射性药物与辐射防护

首次人体成像使用[11C]MDTC:一种靶向2型大麻素受体的放射性示踪剂

First-in-human imaging using [11C]MDTC: a radiotracer targeting the cannabinoid receptor type 2.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-03-06

该研究在健康成人中首次开展[11C]MDTC PET人体研究,评估其安全性、药代动力学及受体结合可重复性。脑PET与全身PET/CT耐受良好,脑区分布容积VT值低,提示脑内CB2R表达低;VT重测平均绝对变异为9.91%,有效剂量为5.29 μSv/MBq。作者建议在将[11C]MDTC PET用于评估活化小胶质细胞CB2R高表达前,先鉴定其放射性代谢物。

要点

  • [11C]MDTC脑PET与全身PET/CT在健康成人中耐受良好,有效剂量为5.29 μSv/MBq。
  • 脑区分布容积VT值低,提示脑内CB2R表达低;VT重测平均绝对变异为9.91%。
  • 作者建议未来研究先鉴定[11C]MDTC的放射性代谢物,再用于评估活化小胶质细胞CB2R高表达。

核心结论

  • 这些数据展示了[11C]MDTC在健康人脑PET中的安全性和药代动力学行为。
  • 作者建议在未来将[11C]MDTC PET用于评估人脑活化小胶质细胞CB2R高表达之前,先开展研究鉴定[11C]MDTC的放射性代谢物。

研究设计与样本

  • 首次人体研究,10名健康成人接受[11C]MDTC动态PET成像,采用90分钟动态PET方案。
  • 5名参与者完成第二次[11C]MDTC PET扫描以评估受体结合结果的重测可重复性。
  • 采用组织隔室模型评估[11C]MDTC在人脑中的动力学行为。
  • 另4名健康成人完成全身[11C]MDTC PET/CT以计算器官剂量和全身有效剂量。

主要发现

  • [11C]MDTC脑PET和[11C]MDTC全身PET/CT耐受良好。
  • 一项小鼠研究发现存在脑渗透性放射性代谢物的证据。
  • 拟合各脑感兴趣区时间活度曲线(TAC)的选用模型为三组织隔室模型,该模型包含独立的输入函数和脑渗透性代谢物隔室。
  • 各脑区分布容积VT值低,提示脑内CB2R表达低。
  • VT重测可靠性显示平均绝对变异为9.91%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 作者建议在未来将[11C]MDTC PET用于评估人脑活化小胶质细胞CB2R高表达之前,先开展研究鉴定[11C]MDTC的放射性代谢物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report findings from the first-in-human study of [11C]MDTC, a radiotracer developed to image the cannabinoid receptor type 2 (CB2R) with positron emission tomography (PET). METHODS: Ten healthy adults were imaged according to a 90-min dynamic PET protocol after bolus intravenous injection of [11C]MDTC. Five participants also completed a second [11C]MDTC PET scan to assess test-retest reproducibility of receptor-binding outcomes. The kinetic behavior of [11C]MDTC in human brain was evaluated using tissue compartmental modeling. Four additional healthy adults completed whole-body [11C]MDTC PET/CT to calculate organ doses and the whole-body effective dose. RESULTS: [11C]MDTC brain PET and [11C]MDTC whole-body PET/CT was well-tolerated. A murine study found evidence of brain-penetrant radiometabolites. The model of choice for fitting the time activity curves (TACs) across brain regions of interest was a three-tissue compartment model that includes a separate input function and compartment for the brain-penetrant metabolites. Regional distribution volume (VT) values were low, indicating low CB2R expression in the brain. Test-retest reliability of VT demonstrated a mean absolute variability of 9.91%. The measured effective dose of [11C]MDTC was 5.29 μSv/MBq. CONCLUSION: These data demonstrate the safety and pharmacokinetic behavior of [11C]MDTC with PET in healthy human brain. Future studies identifying radiometabolites of [11C]MDTC are recommended before applying [11C]MDTC PET to assess the high expression of the CB2R by activated microglia in human brain.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Du Y, Coughlin JM, Brosnan MK, et al. First-in-human imaging using [11C]MDTC: a radiotracer targeting the cannabinoid receptor type 2. Eur J Nucl Med Mol Imaging. 2023. PMID: 36877235. doi:10.1007/s00259-023-06170-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。